Compare SRRK & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | ATAT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.1B |
| IPO Year | 2018 | 2021 |
| Metric | SRRK | ATAT |
|---|---|---|
| Price | $48.29 | $33.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $56.17 | $49.00 |
| AVG Volume (30 Days) | ★ 1.1M | 991.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.06% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.48 |
| Revenue Next Year | $534.24 | $18.11 |
| P/E Ratio | ★ N/A | $26.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $29.81 |
| 52 Week High | $51.63 | $43.17 |
| Indicator | SRRK | ATAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 34.27 |
| Support Level | $45.28 | N/A |
| Resistance Level | $51.34 | $39.19 |
| Average True Range (ATR) | 2.39 | 1.47 |
| MACD | -0.06 | -0.42 |
| Stochastic Oscillator | 50.94 | 1.48 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.